1-2 of 2
Keywords: Hypomethylating agents
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dose Reduced Induction Therapy (A)-AIDA in Patients with Acute Myeloid Leukemia, Being Unfit for Standard 7+3 Chemotherapy and Literature Review of Acute Myeloid Leukemia Treatment in Unfit/Older AML Patients

Available to Purchase
Subject Area:
Hematology , Oncology
Karin Mayer, Leonie Birk, Katjana Schwab, Ingo G.H. Schmidt-Wolf, Marie von Lilienfeld-Toal, Peter Brossart, Axel Glasmacher, Corinna Hahn-Ast
Journal: Acta Haematologica
Acta Haematol (2025)
https://doi.org/10.1159/000545792
Published Online: 05 May 2025
..., older and frail patients cannot be treated intensively. Before hypomethylating agents (HMA) plus venetoclax (VEN) was established we formulated a more tolerable induction therapy for these patients using continuous infusions of reduced doses of cytarabine (A) and idarubicin (IDA) in combination...
View articletitled, Dose Reduced Induction Therapy (A)-AIDA in Patients with Acute Myeloid Leukemia, Being Unfit for Standard 7+3 Chemotherapy and Literature Review of Acute Myeloid Leukemia Treatment in Unfit/Older AML Patients
Open the PDF for Dose Reduced Induction Therapy (A)-AIDA in Patients with Acute Myeloid Leukemia, Being Unfit for Standard 7+3 Chemotherapy and Literature Review of Acute Myeloid Leukemia Treatment in Unfit/Older AML Patients in another window
Journal Articles

Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation

Available to Purchase
Subject Area:
Hematology , Oncology
Lia Minculescu, Joanne Reekie, Soeren Lykke Petersen, Brian Thomas Kornblit, Ida Schjoedt, Niels Smedegaard Andersen, Lisbeth Pernille Andersen, Anne Fischer-Nielsen, Eva Kannik Haastrup, Lone Smidstrup Friis, Henrik Sengelov
Journal: Acta Haematologica
Acta Haematol (2024) 147 (3): 325–332.
https://doi.org/10.1159/000534315
Published Online: 12 October 2023
... in patients who relapse after allogeneic stem cell transplantation (allo-HSCT). During the last decade, the hypomethylating agent Azacitidine has been used together with DLI for a synergistic graft-versus-leukemia (GVL) effect. Here, we report results of DLI/Azacitidine treatment from a retrospective single...
View articletitled, Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation
Open the PDF for Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation in another window